Such intriguing interactions between opioid receptor antagonists and oxytocin outlined in our study may be of clinical relevance given that naltrexone is an FDA-approved medication for the treatment of alcohol use disorders [96], which presents high comorbidity with mood and anxiety disorders, and oxytocin is currently under study for the same indication (ClinicalTrials.gov: NCT03878316). This evidence concerns the gene OXT and anxiety disorder.